Search

The All Eyes Foundation

At its core, All Eyes Foundation (AEF) wishes to help bring vision back to Iraq, and it intends to do this through ophthalmic subspecialty training, mentoring and infrastructure development. Based in Najaf, just over 100 miles south of Baghdad, the...

Ridley Eye Foundation’s Spring camp programme

The Ridley Eye Foundation continues its work in taking surgery to patients in remote communities living above 2000m in Nepal’s Himalayas. This spring, between 28 March – 7 April 2024, we supported surgical camps in Jumla and Mugu, both in...

Touching base with Peter Holland, CEO of the IAPB

For the upcoming Eye News Dec/Jan 2025, our co-editor, David Lockington, had the opportunity to sit down with the CEO of IAPB, Peter Holland. We’re really excited to share this interview with you, which delves into Peter’s fascinating career and...

Advanced level practice for ophthalmic nursing

The Royal College of Nursing (RCN) Ophthalmic Nursing Forum (ONF) is committed to clinical excellence through advancing ophthalmic nursing practice and supporting career development. With the increasing demand for ophthalmic services, advanced and specialist practice roles are vital to increase...

My top five: Trinkets of fact or fiction

Trinkets of adult wisdom are often delivered to children alongside warnings of catastrophic outcomes. In this article we present five ‘facts’ about eye health and vision and ask the question: to what extent are these ideas backed up by literature?...

Effective management of dry eye and ocular surface disease

Experts recommend a consistent approach to diagnosis, therapeutic targeting by disease subtype and escalation of therapy when tear substitutes are not sufficient. Experts call for a consistent, unified approach to diagnosis of dry eye disease (DED), with a new simple...

Shifting the paradigm of managing patients in medical retina: how real-world data can help us to improve clinical practice

The ophthalmic subspecialty of ‘medical retina’ has undergone dramatic changes in recent years. With the introduction of ranibizumab (Lucentis, Novartis), a specialty formerly dominated by laser-based therapies has been transformed to become, in large part, pharmacotherapy-based. To date, these pharmacotherapies...